Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|PBTC-049||PBTC||A Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma and CNS tumors harboring MET aberrations||Pediatric CIRB||Available to Open|
|ABTC-1801||ABTC||Phase I/II Study of Pamiparib (BGB-290) with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations||Adult CIRB - Early Phase Emphasis||Available to Open|
|ABTC-1802||ABTC||A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor||Adult CIRB - Late Phase Emphasis||Available to Open|
|ABTC-1701||ABTC||Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients||Adult CIRB - Early Phase Emphasis||Available to Open|
|ABTC-1804||ABTC||Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with Gliomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|CITN-14||CITN||A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|PEPN1812||PEP-CTN||A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|